An FDA-Approved Drug Structurally and Phenotypically Corrects the K210del Mutation in Genetic Cardiomyopathy Models

Nguyen, NgocUyenNhi. 2025. “An FDA-Approved Drug Structurally and Phenotypically Corrects the K210del Mutation in Genetic Cardiomyopathy Models”. Journal of Clinical Investigation 32 (7): 1789-1804.

Publisher's Version

Last updated on 08/19/2025

Principal Investigator

Principal Investigator Ngoc Uyen Nhi Nguyen, B.Sc., M.Sc., Ph.D.

Internal Medicine/Cardiology, Morsani College of Medicine, University of South Florida

Center for Regenerative Medicine, University of South Florida Health Heart Institute

See also: Principal Investigator

Current Members

Ching-Cheng Hsu, B.Sc., M.Sc., Ph.D.

See also: Current Members